Data in Brief (Feb 2018)

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world

  • Anselm K. Gitt,
  • Dominik Lautsch,
  • Jean Ferrières,
  • Gaetano M. De Ferrari,
  • Ami Vyas,
  • Carl A. Baxter,
  • Lori D. Bash,
  • Veronica Ashton,
  • Martin Horack,
  • Wael Almahmeed,
  • Fu-Tien Chiang,
  • Kian Keong Poh,
  • Philippe Brudi,
  • Baishali Ambegaonkar

Journal volume & issue
Vol. 16
pp. 369 – 375

Abstract

Read online

DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8% receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9% of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32% of all patients received laboratory lipid testing. 37% attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied. Conclusions: Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event. Keywords: Low-density lipoprotein cholesterol, Treatment target, Global, Region, Statins